GSDME Enhances Cisplatin Sensitivity to Regress Non-Small Cell Lung Carcinoma by Mediating Pyroptosis to Trigger Antitumor Immunocyte Infiltration

Dear Editor, Non-small cell lung cancer(NSCLC)is the most common type of lung cancers.Since the majority of NSCLC patients are diagnosed at the advanced stage with a dramatic impact on the prognosis,chemotherapy is still the mainstay of treatment.Cisplatin(CDDP)remains one of the most widely used first-line drugs in the therapy of NSCLC,based on the clinical data that the poor outcomes of untreated NSCLC patients(5％overall survival at 1 year)have shown improvements in natural history of disease after CDDP-based chemotherapy(15％overall survival at 1 year).1 Never-theless,Cisplatin has strong toxic side effects and many NSCLC patients treated with CDDP are easy to occur drug insensitivity,near-to-invariably leading to relapse and therapeutic failure.